1. Home
  2. Solutions
  3. All case studies

Case studies

Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.

Highlights

We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.

By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.

All case studies

Filter our case studies by categories, selecting amongst our broad range of solutions.

Natural Killer Cells

Successful adaptation to complex dose escalation

ICON was selected by a mid-size biotech company to support a phase 1 dose escalation and cohort expansion study of an immune checkpoint inhibitor, in patients with advanced solid tumors. Mid-study, the sponsor was acquired by a large pharma company to which ICON has efficiently supported the transition to the evolving sponsor business model and operations.
Read more
woman looking into microscope in lab

H1N1 vaccine study

A sponsor approached ICON during an influenza pandemic in Mexico to conduct a randomised, placebo controlled vaccine study with an investigative pandemic H1N1 vaccine.
Read more
female-with-mask-avoiding-covid

Exceeding recruitment timelines

ICON was awarded a global study for Major Depressive Disease (MDD) in over 600 adult subjects. Enrollment began during the COVID pandemic and despite challenging protocol requirements, IMP expiry date and database lock requirements, ICON reached LPR and DBL closed five months early.
Read more
Laboratory samples

Successfully completing CGT study recruitment

ICON supported a phase 1/2/3, single-arm, open-label, multi-site, single dose in patients with transfusion-dependent ß-thalassemia. ICON overcame patient recruitment challenges due to the complexity of the study and sites with limited experience with CRISPR-Cas9 modified gene therapy. All planned milestones were met, and first patient randomised was per plan.
Read more
Doctor and Patient (9)

Phase 3 in primary immune thrombocytopenia

ICON was approached by a drug development sponsor to conduct a global, phase 3 trial in an adult patients with primary immune thrombocytopenia. The trial was part of a four-program study with challenging recruitment timelines.
Read more
Immuno-Oncology-non-small-cell-lung-cancer

Hybrid clinical trial model in a Lupus Nephritis study

The sponsor contracted ICON to conduct a randomised trial using a traditional site-based approach to identify the target dose and investigate the safety, tolerability and efficacy of three doses of an investigative compound administered subcutaneously for the treatment of lupus nephritis.
Read more

Solutions case studies

Our solutions span the entire lifecycle of product development and can be adapted to suit small local trials or large global programs. Explore our work in the different aspects of our solutions.

Let's collaborate

Discover how ICON's expertise transforms clinical trials.